SCHEMBL1506088

SCHEMBL1506088

COC(=O)Cc1cc(Nc2cccc(OC(F)(F)F)c2)nn1-c1cc(C)nc(C)c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GALR2 O43603 3/20 0.42
▸ GALR1 P47211 2/20 0.42
▸ NPY5R Q15761 1/20 0.42
▸ IGF1R P08069 2/20 0.42
▸ P2RX3 P56373 3/20 0.40
▸ BRAF P15056 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ PIM1 P11309 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ SYK P43405 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506469 0.91 MAPK1 (0.46) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL1505927 0.90 SYK (0.42) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL1506125 0.88 MAPK1 (0.42) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL1505762 0.88 GALR2 (0.40) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL10009094 0.87 GALR2 (0.41) GALR2GALR1NPY5RBRAFPIM1
SCHEMBL1506116 0.85 CYP3A4 (0.45) GALR2GALR1NPY5RBRAFPIM1
SCHEMBL1506166 0.83 IGF1R (0.41) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL10010866 0.81 MAPK1 (0.46) GALR2GALR1NPY5RIGF1RBRAF
SCHEMBL10008198 0.81 GALR2 (0.43) GALR2GALR1NPY5RIGF1RP2RX3
SCHEMBL10009161 0.80 MAPK1 (0.50) GALR2GALR1NPY5RIGF1RP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 GALR2 201/4885GALR1 89/4885NPY5R 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback